L
Laura C. A. Galbraith
Researcher at University of Glasgow
Publications - 23
Citations - 1405
Laura C. A. Galbraith is an academic researcher from University of Glasgow. The author has contributed to research in topics: Prostate cancer & Cancer research. The author has an hindex of 9, co-authored 18 publications receiving 1015 citations. Previous affiliations of Laura C. A. Galbraith include Walter and Eliza Hall Institute of Medical Research & University of Melbourne.
Papers
More filters
Journal ArticleDOI
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy,Szlávik Zoltán,James A. H. Murray,James Edward Paul Davidson,Ana Leticia Maragno,Gaëtane Le Toumelin-Braizat,Maïa Chanrion,Gemma L. Kelly,Gemma L. Kelly,Jia-Nan Gong,Jia-Nan Gong,Donia M Moujalled,Alain Bruno,Csékei Márton,Attila Paczal,Zoltán B. Szabó,Szabolcs Sipos,Gabor Radics,Proszenyák Ágnes,Balázs Bálint,Levente Ondi,Gábor Blasko,Alan P. Robertson,Allan E. Surgenor,Pawel Dokurno,Chen I-Jen,Natalia Matassova,Julia Smith,C. Pedder,Chris Graham,Aurélie Studeny,Gaëlle Lysiak-Auvity,Anne-Marie Girard,Fabienne Gravé,David J. Segal,David J. Segal,Chris D. Riffkin,Chris D. Riffkin,Giovanna Pomilio,Laura C. A. Galbraith,Laura C. A. Galbraith,Brandon J. Aubrey,Brandon J. Aubrey,Brandon J. Aubrey,Margs S. Brennan,Margs S. Brennan,Marco J Herold,Marco J Herold,Catherine Chang,Catherine Chang,Ghislaine Guasconi,Nicolas Cauquil,Fabien Melchiore,Nolwen Guigal-Stephan,Brian Lockhart,Frédéric Colland,John A. Hickman,Andrew W. Roberts,David C.S. Huang,David C.S. Huang,Andrew H. Wei,Andrew H. Wei,Andreas Strasser,Andreas Strasser,Guillaume Lessene,Guillaume Lessene,Olivier Geneste +66 more
TL;DR: It is demonstrated that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway.
Journal ArticleDOI
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Franziska Baenke,Barbara Chaneton,Matthew Smith,Niels J. F. van den Broek,Kate Hogan,Haoran Tang,Amaya Viros,Matthew J. Martin,Laura C. A. Galbraith,Maria Romina Girotti,Nathalie Dhomen,Eyal Gottlieb,Richard Marais +12 more
TL;DR: It is shown that BRAF mutant melanoma cells that have developed acquired resistance to BRAF inhibitors display increased oxidative metabolism and increased dependency on mitochondria for survival, suggesting that targeting specific metabolic pathways may offer exciting therapeutic opportunities to treat resistant tumors, or to delay emergence of resistance in the first‐line setting.
Journal ArticleDOI
Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer
Imran Ahmad,Ernest Mui,Laura C. A. Galbraith,Rachana Patel,Ee Hong Tan,Mark Salji,Alistair G. Rust,Peter Repiscak,Ann Hedley,Elke Markert,Carolyn J. Loveridge,Louise van der Weyden,Joanne Edwards,Owen J. Sansom,David J. Adams,Hing Y. Leung +15 more
TL;DR: It is shown that elevated levels of PPARG strongly correlate with elevation of FASN in human CaP and that high levels ofPPARG/FASN and PI3K/pAKT pathway activation confer a poor prognosis, and it is suggested that CaP patients could be stratified in terms of PP ARG/ fasN and PTEN levels to identify patients with aggressive CaP who may respond favorably to PPARg/FasN inhibition.
Journal ArticleDOI
Lipid pathway deregulation in advanced prostate cancer.
TL;DR: There is growing evidence implicating the role of obesity and peri‐prostatic adipose tissue (PPAT) in PC aggressiveness and related mortality, suggesting the importance of lipid pathways in both localised and disseminated disease.
Journal ArticleDOI
Bright insights into palladium-triggered local chemotherapy
Thomas L. Bray,Mark Salji,Alessandro Brombin,Ana M. Pérez-López,Belén Rubio-Ruiz,Laura C. A. Galbraith,E. Elizabeth Patton,Hing Y. Leung,Asier Unciti-Broceta +8 more
TL;DR: Fundamental insights are reported into the validity, reliability and clinical feasibility of using heterogeneous Pd catalysts as implantable devices to accurately activate chemotherapy within a tumour.